Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.7600 (4.73%) ($5.4800 - $5.7700) on Tue. Oct. 16, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.45% (three month average) | RSI | 63 | Latest Price | $5.7600(4.73%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.5% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) SHY(7%) XHB(6%) DIA(5%) TLT(5%) IPO(4%) | Factors Impacting TGTX price | TGTX will decline at least -3.225% in a week (0% probabilities). XLC(-8%) URA(-8%) ICLN(-7%) BLOK(-7%) XLRE(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.225% (StdDev 6.45%) | Hourly BBV | 0 () | Intraday Trend | 4.3% | | | |
|
Resistance Level | $6.13 | 5 Day Moving Average | $5.56(3.6%) | 10 Day Moving Average | $5.49(4.92%) | 20 Day Moving Average | $6.13(-6.04%) | To recent high | -54.6% | To recent low | 11.8% | Market Cap | $729m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |